Turkish Journal of Biology
Volume 42

Number 3

Article 6

1-1-2018

Differential expression of nucleostemin in the cytoplasm and
nuclei of normal andcancerous cell lines
CHAVALI KAVYASUDHA
JOSEPH JOEL
ARIKKETH DEVI

Follow this and additional works at: https://journals.tubitak.gov.tr/biology
Part of the Biology Commons

Recommended Citation
KAVYASUDHA, CHAVALI; JOEL, JOSEPH; and DEVI, ARIKKETH (2018) "Differential expression of
nucleostemin in the cytoplasm and nuclei of normal andcancerous cell lines," Turkish Journal of Biology:
Vol. 42: No. 3, Article 6. https://doi.org/10.3906/biy-1712-10
Available at: https://journals.tubitak.gov.tr/biology/vol42/iss3/6

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Biology by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Biology

Turk J Biol
(2018) 42: 250-258
© TÜBİTAK
doi:10.3906/biy-1712-10

http://journals.tubitak.gov.tr/biology/

Research Article

Differential expression of nucleostemin in the cytoplasm and nuclei of normal and
cancerous cell lines
Chavali KAVYASUDHA, Joseph P. JOEL, Arikketh DEVI*
Stem Cell Biology Laboratory, Department of Genetic Engineering, SRM University, Kattankulathur, India
Received: 04.12.2017

Accepted/Published Online: 12.04.2018

Final Version: 13.06.2018

Abstract: Studies conducted in the past decade have reported nucleostemin (NS) as a nucleolar protein that has a role in self-renewal
and cell cycle regulation in cancer/stem cells, but is absent in differentiated cells. The localization and expression patterns of NS have
always been disputed, as reports indicate its varied levels among tissues and cells. This study evaluates the expression and localization
pattern of NS in normal cells, cancer cell lines, and stem cells. Our findings revealed that the expression of NS was high in cancers
originating from the skin and liver compared to the normal cell lines. NS knockdown affects the proliferation of normal cell lines,
similar to cancerous cell lines. The localization pattern of NS was analyzed by immunofluorescence, which showed that NS was localized
in the nuclei of normal cell lines but is present both in the nucleus and the cytoplasm of cancerous/stem cell lines. Interestingly, we
observed that siNS cancerous cell lines had lower NS in the cytoplasm, which did not salvage the reduction in proliferation caused by
siNS. We postulate that the loss of NS in the nucleus inhibits the proliferative ability of both normal and cancerous cells at similar rates,
although the role of NS in the cytoplasm apart from proliferation needs to be further explored.
Key words: Cell fractionation, immunocytochemistry, localization, proliferation, RNA interference

1. Introduction
Nucleostemin (NS), is a nucleolar protein that was initially
identified in the neural stem cells of rats (Tsai and McKay,
2002) and in several other cancer cells. It contains two
putative guanosine triphosphate (GTP) binding motifs: the
N-terminal domain, essential for nucleolar localization,
and an acidic C-terminus (Tsai and McKay, 2002). NS is
known to shuttle from the nucleolus to the nucleoplasm
when bound to GTP; this shuttling is regulated by
multiple control mechanisms (Meng et al., 2006; Ma and
Pederson, 2008). The expression of NS is observed to be
high in many cancerous cell types, including squamous
cell carcinoma, head and neck cancers (Cada et al., 2007),
oral squamous cells and cervical carcinoma cells (Ye et
al., 2008; Yoshida et al., 2011), renal cell carcinomas (Fan
et al., 2006a), glioblastoma cells (Bao et al., 2016), brain
cancers (Malakootian et al., 2010), and prostate cancers
(Liu et al., 2008). A similar higher expression was also
observed in embryonic, neural, and hematopoietic stem
cells (Tsai and McKay, 2002; Cai et al., 2003; Nomura et
al., 2009; Lin et al., 2010; Yamashita et al., 2013; Yuan et
al., 2015). However, interestingly, NS was observed to be
downregulated in differentiated cells and noncancerous
cells (Tsai and McKay, 2002; Yaghoobi et al., 2005). From
* Correspondence: adevipradeep@gmail.com
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these studies, it is evident that NS plays a role in the cell
cycle and proliferation of rapidly dividing cells.
Studies of complete loss of NS, either through siRNA
knockdown or proteolytic degradation, lead to p53
upregulation leading to cell cycle arrest or apoptosis,
whereas heterozygous loss leads to cellular senescence
(Zhu et al., 2006; Huang et al., 2011). Based on the tumor
cell type, depletion or knockdown of NS has been shown
to perturb the cell cycle progression either in the G0/G1
phase (U2OS, Saos-2, and HeLa) (Sijin et al., 2004; Ma and
Pederson, 2007; Dai et al., 2008; Seyed-Gogani et al., 2014)
or in the G2/M phase (PC-3, HCT116, K562, MHCC97H,
and bone-marrow-derived stromal stem cells) (Jafarnejad
et al., 2008; Liu et al., 2008; Ma and Pederson, 2008; Nikpour
et al., 2009; Huang et al., 2015; Yuan et al., 2015). Loss of
NS increased the spontaneous DNA damage in cancer
cells by elevating the frequency of telomere damage and
aberration, reducing the telomeric length, and perturbing
the telomeric repeat binding factor 2 (TRF2ΔBΔM-)-induced
telomeric recruitment of Ras associated with diabetes
(RAD51) (Hsu et al., 2012; Lin et al., 2013; Meng et al.,
2013; Yamashita et al., 2013). However, overexpression of
NS interferes with cell cycle progression through the p53
pathway (Tsai and McKay, 2002; Dai et al., 2008).
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Parallelly, multiple studies report that NS is expressed
even in normal cells and tissues such as renal cells,
uroepithelial cells, and oropharyngeal and laryngeal
epithelial cells (Fan et al., 2006a; Cada et al., 2007; Nikpour
et al., 2009). This dispute over the expression of NS formed
the basis of this study, and it is an attempt to clearly
understand the expression pattern and localization of NS
in normal and cancer cell lines, which could thus lay the
foundation to assess the role of NS in the future. In this
study, we observed the expression of NS in both normal
(HaCaT, THLE, HEK 293) and cancerous (A431, HepG2,
A498, HeLa, IMR32, ACHN, HCT116) cell lines. siRNAmediated silencing of NS revealed that the knockdown of
NS reduced the rate of proliferation in HEK 293 (normal
renal), THLE (normal liver), and A498 (cancerous renal)
cell lines. Furthermore, immunocytochemistry and
western blotting analysis revealed that NS differentially
localized in normal and cancer cells. From these results,
we infer that loss of NS inhibits the proliferation of normal
cells similar to that of cancerous cells, and NS may perform
functions other than proliferation in the cytoplasm of
cancerous cells.
2. Materials and methods
2.1. Cell culture
All the cell lines used in the study were procured from
the National Centre for Cell Sciences (NCCS), Pune,
India (Table 1). The cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) (GIBCO; Thermo
Fisher Scientific, Inc., Waltham, MA, USA), supplemented
with 10% fetal bovine serum (FBS) (GIBCO, UK) and
antibiotic-antimycotic solution (GIBCO, UK), and were
maintained at 37 °C in a humidified incubator with 5%
CO2.
2.2. RNA isolation and RT-PCR
The total RNA from all the cancer and normal cell lines was
extracted using TRIzol (Ambion, Life Technologies, USA)
and quantified using the NanoDrop system (NanoDrop
Lite Spectrophotometer, Thermo Scientific, USA). The
extracted RNA was treated with RNase-free DNase (NEB,
UK) and incubated at 28 °C for 1 h and deactivated at
70 °C for 10 min. One microgram of RNA was reverse
transcribed to synthesize cDNA using oligo (dT) and
Moloney murine leukemia virus (Mo-MLV) reverse
transcriptase (NEB, UK). PCR primers were designed using
Table 1. Normal and cancerous cell lines used for the study.
Skin

Liver

Kidney

Normal

HaCaT

THLE

HEK 293

Cancerous

A431

HepG2

A498

Primer3 software and the primer sequences of the genes
are shown in Table 2. PCR amplification was performed
using a thermal cycler (Eppendorf, Hamburg, Germany)
with the following conditions: initial denaturation at 95 °C
for 2 min, followed by 30 cycles of 95 °C for 20 s, 58 °C for
30 s, and 72 °C for 30 s. β-Actin was used as the internal
control. PCR products were separated on a 1% agarose gel
and viewed under a UV transilluminator.
2.3. siRNA transfection
The siRNA targeting NS and nontargeting control siRNA
were purchased from QIAGEN (USA). The day before
transfection, the cells were cultured and seeded in 24well plates. The HEK 293, THLE, and A498 cell lines were
transfected with 65 nM siRNA and 3 µL of HiPerFect
transfection reagent (QIAGEN, USA) and vortexed with
100 µL of serum-free medium. This mixture was incubated
for 10 min at room temperature and then added to the
cells in the plate. The cells were harvested at 24, 48, and 72
h and subjected to western blotting analysis.
2.4. Growth curve analysis
HEK 293, THLE, and A498 cells were transfected with
siRNA targeting NS and control siRNA. Growth curve
analysis was performed by counting the number of cells in
the well every 24 h after transfection over a period of 72 h,
using a hemocytometer.
2.5. MTT assay/cell proliferative assay
The MTT assay was used to evaluate cell proliferation
subsequent to transfection. The cells were cultured
overnight in 96-well plates at a density of 5 × 103 cells/
well and siRNA transfection was performed. Tetrazolium
dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, 5 mg/mL) was added to the culture
medium in each well and incubated for 4 h at 37 °C. The
medium was then removed and the formazan crystals
were dissolved with 150 µL/well of dimethyl sulfoxide
(DMSO). The absorption was measured using an ELISA
Reader (Synergy HTX, BioTek) at 570 nm.
2.6. Immunocytochemistry
The cells were fixed with 4% paraformaldehyde for 15 min at
room temperature, followed by permeabilization with 0.1%
Triton X-100. Cellular proteins were then blocked with 1%
BSA for 1 h at room temperature and then incubated with
primary antibodies overnight in a humidified chamber at 4
°C. After overnight incubation, the cells were washed with
PBS and incubated with secondary antibodies for 1 h at
room temperature. Anti-NS mouse monoclonal primary
antibody (1:200, BD Bioscience, USA), anti-β-actin
mouse monoclonal primary antibody (1:200, Santa Cruz
Biotechnology, USA), and antimouse secondary antibody
(1:400, BD Bioscience, USA) were used for the experiment.
The cells were counterstained with 4’,6-diamidino-2phenylindole (DAPI). The coverslips were mounted using
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Table 2. Gene primers designed for RT-PCR.
Gene
Nucleostemin
β-Actin

Primer

Sequence

Forward primer

5’-GGGAAGATAACCAAGCGTGTG-3’

Reverse primer

5’-CCTCCAAGAAGTTTCCAAAGG-3’

Forward primer

5’-AGAGCTACGAGCTGCCTGAC-3’

Reverse primer

5’-GGATGCCACAGGACTCCA-3’

glycerol and were analyzed in a fluorescence-enabled
inverted microscope (Leica Microsystems, USA).
2.7. Protein isolation and quantification
The cells were lysed using a radio immunoprecipitation
assay (RIPA) buffer (Sigma-Aldrich, USA), kept on ice
for 5 min, and centrifuged at ~14,000 × g for 15 min.
The total protein was collected and stored. The nuclear
and cytoplasmic fractions from the cells were extracted
using an NE-PER Nuclear Cytoplasmic Extraction
Reagent Kit (Pierce, Rockford, IL, USA) according to
the manufacturer’s instructions. Proteins isolated were
quantified using Bradford reagent (Sigma-Aldrich, USA)
based on the Bradford method (Bradford, 1976).
2.8. Western blotting
The total protein, cytoplasmic, and nuclear fractions were
separated by 12% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to
a nitrocellulose membrane (Amersham Protran, GE
Healthcare Life Sciences, Germany) in a semidry blotting
apparatus. The membranes were blocked for 1 h with 3%
bovine serum albumin (BSA) in Tris-buffered saline with
0.1% Tween 20 (TBST). The blocked membranes were
incubated with anti-NS (562749; 1:1000) (BD Biosciences,
USA), anti-β-actin (sc-47778; 1:1000) (Santa Cruz, USA),
and Cdk2 (sc-6248; 1:1000) (Santa Cruz, USA) primary
antibody, prepared in blocking solution at 4 °C overnight.
β-Actin and Cyclin-dependent kinase 2 (Cdk2) were used
as the internal control for the total and nuclear fractions,
respectively. The membranes were then washed with TBST
and incubated with appropriate horseradish peroxidaseconjugated (HRP) secondary antibodies (550946; 1:2000,
BD Biosciences, USA) at room temperature for 2 h. The
blots were then washed with TBST and were visualized
using an enhanced chemiluminescence (ECL) kit (Pierce,
USA) and analyzed using a gel image analysis system.
3. Results
3.1. Nucleostemin was abundantly expressed in
cancerous cell lines and expressed in detectable levels in
normal cell lines
To investigate the NS expression in normal and cancerous
cells, RT-PCR analysis was performed on normal cell lines
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Product size
98 bp
111 bp

(HaCaT - skin, THLE - liver, and HEK 293 - kidney),
which were compared with their cancerous counterparts
(A431, HepG2, and A498) from the same organs of origin.
The results revealed that NS was expressed in detectable
amounts in both normal and cancerous cell lines. However,
its expression levels were found to be significantly higher
in cancerous cell lines of the skin (A431) (Figure 1a) and
liver (HepG2) (Figure 1b) compared with normal cells. In
the kidney cell line (A498), NS expression was found to be
lower in the cancerous cells (Figure 1c).
3.2. siRNA-mediated knockdown of nucleostemin
inhibited the rate of proliferation of rapidly dividing
cancerous as well as normal renal cell lines
The high expression of NS in cancer cell lines A431 and
HepG2 could be due to the increased proliferation rate
of the cancer cells, and to determine the effect of NS in
proliferation of the cell lines, transient silencing of NS
was performed on normal renal (HEK 293), normal
liver (THLE), and renal carcinoma (A498) cell lines,
which were the most rapidly dividing cell lines from
our selection. Silencing of the NS gene was achieved by
transiently transfected siRNA. To optimize the efficacy of
the siRNA, these cell lines were transfected with different
concentrations of siNS (40, 50, and 65 nM) and the results
revealed that the highest knockdown was obtained with
65 nM concentration of siNS at 72 h after transfection.
Silencing of NS was verified using western blotting analysis,
which confirmed the highest inhibition at 72 h (Figure 2a),
and no significant downregulation was observed in 24 and
48 h (Supplementary Figure A). A growth curve plotted
with cell numbers counted over a 24-h time plot showed
a significant decrease in the proliferation of siNS cells
compared to the control for HEK 293, THLE, and A498
cell lines (Figure 2b). The decrease in proliferation was
further confirmed by the MTT assay (Figure 2c).
3.3. Nucleostemin was localized in the nucleus and
cytoplasm of both cancerous cells and stem cells
Immunocytochemistry was performed to investigate
the localization of NS in normal cells (HaCaT, THLE,
and HEK 293), cancerous cell lines (A431, HepG2, and
A498), and mesenchymal stem cells (MSCs) derived from
dental pulp cells (Figures 3a–3d). The results revealed
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Figure 1. NS expression was upregulated in cancerous cell lines compared to normal cells. RT-PCR analysis revealed higher expression
of NS in skin (a) and liver carcinoma (A431 and HepG2) (b) compared to their normal cell lines (HaCaT and THLE), except in the
renal carcinoma cell line (A498) (c), where NS expression was lower compared to its normal cell line (HEK 293). The corresponding
densitometry analysis of mRNA expression is shown in (d). *P < 0.05.

that NS was localized in both the cytoplasmic and nuclear
compartments of all the stem cells and cancerous cell
lines, while being limited only to the nuclei of normal
cells (Figure 3e). Immunoblotting of the NS antibody
on fractionated total, nuclear, and cytoplasmic protein
samples from these cell lines also confirmed the expression
pattern observed in immunocytochemistry. These
immunological experiments were also performed on
other cancerous cell lines: cervical carcinoma (HeLa),
neuroblastoma (IMR32), renal carcinoma (metastatic)
(ACHN), colon cancer (HCT116), and human oral
squamous cell carcinoma (OSCC) T4 stage cancer tissue
samples, which also presented a similar expression pattern
of NS (Supplementary Figures B and C). Interestingly, the
immunolocalization analysis of NS in siRNA knockdown
cancerous cells (A498) showed a predominant reduction
of NS expression in the nucleus (Figure 3f), with a lower
but detectable expression in the cytoplasm.
4. Discussion
The localization and expression profiles of NS have always
been a debated issue in the mechanism of NS action,
which was primarily reported as a nucleolar protein

identified in stem and cancer cells (Tsai and McKay, 2002;
Kafienah et al., 2006; Nomura et al., 2009; Yamashita et
al., 2013). Parallelly, a number of studies of normal renal
tissues, uroepithelial cells, and normal oropharyngeal
and laryngeal epithelial cells also showed NS expression
(Tsai and McKay, 2002; Fan et al., 2006a; Nikpour et al.,
2009). This study examined this issue by comparing the NS
expression and localization profiles in stem cells (MSCs)
derived from dental pulp cells, cancerous cells, and
normal cells. Earlier studies reported that NS expression
levels vary among tissues (Tsai and McKay, 2002; Fan et
al., 2006b; Malakootian et al., 2010; Li et al., 2015), and to
analyze this variation profile, RT-PCR was performed for
both normal and cancerous cell lines. Overexpression of
NS was observed in HEK 293 when compared to the A498
cell line (Figure 1c) and this might be due to the fact that
HEK 293 was derived from the human embryonic kidney
and it may retain gene expression traits observed during
early development. Since NS expression was observed
even in normal cells, it is critical to analyze if the loss of NS
would affect the proliferation of normal cells to the extent
that it affects the cancerous cell lines. Interestingly, siRNAmediated transient silencing of NS on HEK 293 and A498
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Figure 2. Inhibition of NS affects the rate of proliferation in rapidly dividing cancerous as well as in normal cells. (a) Western blotting
analysis of HEK 293, A498, and THLE cell lines transfected with siRNA targeting NS and nontargeting control siRNA shows optimal
inhibition of NS in HEK 293, A498, and THLE cell lines at 72 h after transfection. (b) The corresponding densitometry analysis of
protein expression is shown. (c) siNS transfection was accompanied with a significant decrease in the proliferation ability of the cells at
the 72-h time point. (d) MTT assay with a significant decrease in the cell proliferation rate of HEK 293, THLE, and A498 cell lines. *P
< 0.05, **P < 0.01.
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Figure 3. Expression of NS was observed in the nucleus and cytoplasm of cancerous cells and stem cells. Immunolocalization studies were performed
on cancerous cells paired with normal cells derived from the same tissues of origin: skin (A431 vs. HaCaT) (a), liver (HepG2 vs. THLE) (b), and kidney
(A498 vs. HEK293) (c), and in each case NS was found to be localized in the cytoplasm and nuclei of cancerous cells, but it was restricted to the nuclei
of normal cells. The expression patterns of NS in MSCs were also observed to resemble those of the cancerous cells (d). All the immunolocalization
experiments were confirmed with immunoblotting of the total (TP), nuclear (NP), and cytoplasmic (CP) fractionated protein samples. Schematic
representation of the overall outcome of the results is depicted (e). Immunolocalization analysis of siRNA-mediated knockdown NS in cancerous cells
(A498) predominantly reduced the nuclear expression (f). β-Actin (42 kDa) and CDK (34 kDa) were used as the loading control for total protein and
nuclear fraction, respectively (200× magnification).

255

KAVYASUDHA et al. / Turk J Biol
cells revealed that loss of NS decreased the proliferation of
cancerous and normal cells at similar rates. These results
suggest that NS was required for proliferation of not only
cancerous cells but also for rapidly dividing noncancerous
cells. Innumerable studies have also proven that NS is
involved in controlling the proliferation of stem cells (Tsai
and McKay, 2002. Beekman et al., 2006; Kafienah et al.,
2006; Jafarnejad et al., 2008; Nomura et al., 2009).
NS is primarily reported to be a nucleolar protein
that interacts with several proteins, including p53, mouse
double minute 2 (MDM2), nucleophosmin (NPM),
ribosomal L1 domain containing protein 1 (RSL1D1),
telomeric repeat binding factor 1 (TRF1), and alternate
reading frame (ARF), thereby involved in self-renewal,
cell cycle regulation, pre-RNA processing, apoptosis, and
cell proliferation (Bernardi and Pandolfi, 2003; Beekman
et al., 2006; Zhu et al., 2006; Ma and Pederson, 2007, 2008;
Dai et al., 2008; Meng et al., 2008, 2013; Nomura et al.,
2009; Lo and Lu, 2010; Zwolinska et al., 2012). Since the
localization of NS in the nucleus is important for these
functions, the variation in the distribution pattern of NS in
cancerous and normal cell lines was studied. Earlier studies
reported that NS is physically associated with MDM2 and
functionally linked to p53 inactivation (Tsai and McKay,
2002; Ma and Pederson, 2007; Dai et al., 2008), while a few
reported that NS remains indispensable for the survival and
proliferation of p53 null normal or cancer cells (Beekman
et al., 2006; Jafarnejad et al., 2008; Meng et al., 2013). The
p53 properties of all the cell lines used in the study were
analyzed, which revealed that the normal skin cell line
(HaCaT) had mutated p53, but it is unclear whether p53
activity is still functional regarding induction of apoptosis,
whereas the skin carcinoma cell line (A431) has no
functional p53 and is highly sensitive to mitogenic signals.
The hepatocarcinoma cell line (HepG2) expresses normal
p53 levels, while the other cell lines, including normal renal
(HEK 293), normal liver (THLE), colon cancer (HCT116),
cervical carcinoma (HeLa), neuroblastoma (IMR32), and
renal carcinoma (A498, ACHN) cell lines, have wild-type
p53. Surprisingly, our immunocytochemistry analysis
revealed variation in distribution patterns of NS in normal,
cancerous, and stem cells.

As immunofluorescence results can be affected by
many factors such as cell morphology, fixation methods, or
nonspecific binding of antibodies, the immunofluorescence
data were confirmed by immunoblotting by performing
subcellular fractionation of the total, nuclear, and
cytoplasmic extracts of cells to support the data and
ascertain whether the results correlated with the
immunofluorescence data. Our data on the localization
pattern of NS were concordant with earlier reports on renal
cell carcinoma tissues, gastric cancer cells, and colon cancer
cells (Han et al., 2005; Yang et al., 2005; Fan et al., 2006c).
Immunolocalization experiments on siRNA-mediated NS
inhibited cancerous (A498) (Figure 3f) and normal (HEK
293) (Supplementary Figure D) cell lines. Interestingly, NS
was predominantly downregulated in the nuclei of both cell
types. However, a lower but detectable quantity of NS was
present in the cytoplasm of cancerous cells. The fact that this
cytoplasmic NS could not salvage the proliferation of the
cells suggests that NS plays a role other than proliferation
when localized in the cytoplasm of cancerous cells. Thus, it
is likely that different NS localizations between cancerous/
stem and normal cells may be related to the different
functional activities of these cell types. Furthermore, the
functional activity of shuttling and specific target genes of
this protein between the nucleus and cytoplasm of these
cells remains to be resolved and established.
Overall, from this study, we postulate that NS was
required for proliferation of not only cancerous cells but
also for rapidly dividing noncancerous cells. Furthermore,
NS is localized both in the nucleus and cytoplasm of
cancerous cell lines, but only in the nucleus of normal cell
lines. Thus, we suggest that NS may perform functions
other than proliferation in the cytoplasm of cancerous cells.
Moreover, evaluating the target genes of these proteins
within the nucleus and cytoplasm of these cells could
contribute to cancer treatment.
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Supplementary Figure A. Western blotting analysis of HEK 293 and A498 cell lines
transfected with siRNA targeting NS and control siRNA showed no inhibition of NS at 24
and 48 h following transfection.

Supplementary Figure B. Immunofluorescence and immunoblotting analysis on other cancerous cell lines showed nuclear and
cytoplasmic localization of NS (200× magnification).

Supplementary Figure C. Immunofluorescence analysis of NS in T4 OSCC cancerous tissues showed nuclear
and cytoplasmic localization of NS (400× magnification).
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Supplementary Figure D. Immunolocalization analysis of siRNA-mediated knockdown NS in normal cells (HEK 293) showed reduced
NS expression in the nucleus (200× magnification).
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